BPG is committed to discovery and dissemination of knowledge
Articles in Press
11/21/2020 5:41:51 AM | Browse: 236 | Download: 125
Publication Name World Journal of Clinical Cases
Manuscript ID 59388
Country/Territory France
Category Oncology
Manuscript Type Case Report
Article Title Pembrolizumab as a novel therapeutic option for patients with refractory thymic epithelial tumor: A case report
Manuscript Source Unsolicited Manuscript
All Author List Jonathan Wong-Chong, Maureen Bernadach, Angeline Ginzac, Hugo Veyssière and Xavier Durando
Funding Agency and Grant Number
Corresponding Author Hugo Veyssière, N/A, N/A, Division de Recherche Clinique, Délégation Recherche Clinique et Innovation, Centre Jean PERRIN, 58 rue Montalembert, Clermont-Ferrand 63011, France. hugo.veyssiere@clermont.unicancer.fr
Key Words Thymic epithelial carcinoma; Programmed death-ligand 1 negative; Pembrolizumab; Immune checkpoint; Metastasis; Case report
Core Tip Thymic epithelial carcinomas are rare and have poor prognosis. The overall 5-year survival rate for patients with thymic carcinoma is about 30%–50%. We present the case of a 45-year-old Caucasian male who presented with hepatalgia and a cervical mass, and was diagnosed with programmed death-ligand 1-negative metastatic thymic carcinoma. The patient underwent pretreatment with platinum-based chemotherapy, after which pembrolizumab was administered as salvage therapy and complete metabolic response was achieved.
Citation Wong-Chong J, Bernadach M, Ginzac A, Veyssière H, Durando X. Pembrolizumab as a novel therapeutic option for patients with refractory thymic epithelial tumor: A case report. World J Clin Cases 2021; 9(5): 1139-1147
2020-10-26 08:01
Peer-Review Started
2020-10-26 08:01
To Make the First Decision
Return for Revision
2020-11-03 00:14
2020-11-12 08:48
Second Decision
2020-11-17 12:42
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2020-11-21 05:41
Articles in Press
2020-11-21 05:41
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2021-01-06 01:37
ISSN 2307-8960 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Assistant Editor Assistant Editor
Science Editor Jia-Ru Fan
Reviewer Code 03724988
Editorial Director
Journal Chief Editor
Company Chief Editor Lian-Sheng Ma
Language Editor
Production Editor Yan-Liang Zhang
Responsible Production Editor Jia-Hui Li
Responsible Science Editor
Proofing Editorial Director Jin-Lei Wang
Proofing Editor-in-Chief Lian-Sheng Ma
Full Article (PDF) WJCC-9-1139.pdf
Full Article (Word) WJCC-9-1139.docx
Manuscript File 59388_Auto_Edited.docx
Answering Reviewers 59388-Answering reviewers.pdf
Audio Core Tip 59388-Audio core tip.m4a
Conflict-of-Interest Disclosure Form 59388-Conflict-of-interest statement.pdf
Copyright License Agreement 59388-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s) 59388-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate 59388-Language certificate.pdf
Peer-review Report 59388-Peer-review(s).pdf
Scientific Misconduct Check 59388-Bing-Ma YJ-1.jpg
Scientific Misconduct Check 59388-Bing-Fan JR-2.png
Scientific Misconduct Check 59388-Scientific misconduct check.pdf
Scientific Editor Work List 59388-Scientific editor work list.pdf